Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 10/20 | 0.87 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.87 |
| ▸ | CDK2 | P24941 | 12/20 | 0.82 |
| ▸ | CCNE2 | O96020 | 10/20 | 0.82 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.82 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.73 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.73 |
| ▸ | PDE5A | O76074 | 1/20 | 0.73 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.73 |
| ▸ | CDK7 | P50613 | 1/20 | 0.73 |
| ▸ | CDK9 | P50750 | 1/20 | 0.73 |
| ▸ | CCNH | P51946 | 1/20 | 0.73 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.73 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.73 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.66 |
| ▸ | CLK2 | P49760 | 1/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.66 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277404 | 0.93 | CDK1 (1.00) | CDK1CDK5CDK2CCNE2CCNE1 | |
| SCHEMBL3332989 | 0.89 | CDK1 (0.76) | CDK1CDK5CDK2CCNE2CCNE1 | |
| SCHEMBL14071580 | 0.88 | CDK2 (0.85) | CDK1CDK5CDK2CCNE2CCNE1 | |
| SCHEMBL3680752 | 0.86 | CCNE1 (0.82) | CDK1CDK5CDK2CCNE2CCNE1 | |
| SCHEMBL6143053 | 0.86 | CDK2 (1.00) | CDK1CDK5CDK2CCNE2CCNE1 | |
| SCHEMBL1394958 | 0.84 | CCNE2 (1.00) | CDK1CDK5CDK2CCNE2CCNE1 | |
| SCHEMBL5827556 | 0.83 | CCNE2 (0.78) | CDK1CDK5CDK2CCNE2CCNE1 | |
| SCHEMBL7098593 | 0.83 | KDM4E (0.70) | CDK1CDK5CDK2CCNE2CCNE1 | |
| SCHEMBL17450143 | 0.82 | CDK1 (0.66) | CDK1CDK5CDK2CCNE2CCNE1 | |
| SCHEMBL17450111 | 0.82 | CDK1 (0.66) | CDK1CDK5CDK2CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016200726-A1 | INHIBITORS OF MCI-1 AS DRUGS TO OVERCOME RESISTANCE TO BRAF INHIBITORS AND MEK INHIBITORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2016-12-15 | — | — | WO | claimed |
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | claimed |
| WO-2015153657-A2 | OVERCOMING CHEMOTHERAPEUTIC AGENT RESISTANCE IN CANCER BY INHIBITING MCL-1 | TEXAS TECH UNIVERSITY SYSTEM (US) | 2015-10-08 | — | — | WO | claimed |
| EP-2747755-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | claimed |
| EP-2748331-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | claimed |
| WO-2013026874-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | claimed |
| WO-2013026890-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | claimed |
| EP-2076268-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF CYSTIC DISEASES | Genzyme Corporation (US) | 2009-07-08 | — | — | EP | claimed |
| WO-2008051502-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF CYSTIC DISEASES | GENZYME CORPORATION (US) | 2008-05-02 | — | — | WO | claimed |
| EP-3256484-A1 | NON-MEMBRANE DISRUPTIVE p53 ACTIVATING STAPLED PEPTIDES | Agency For Science, Technology And Research (SG) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017205514-A1 | METHODS OF SENSITIZING CANCER TO IMMUNOTHERAPY | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2016200726-A1 | INHIBITORS OF MCI-1 AS DRUGS TO OVERCOME RESISTANCE TO BRAF INHIBITORS AND MEK INHIBITORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016146833-A1 | BIOMARKERS FOR NAD(+)-DIPHTHAMIDE ADP RIBOSYLTRANSFERASE RESISTANCE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016130092-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-08-18 | — | — | WO | disclosed |
| WO-2003077999-A1 | COMBINATION OFA CDK INHIBITOR AND 5-FU FOR THE TREATMENT OF CANCER | CYCLACEL LIMITED (GB) | 2003-09-25 | — | — | WO | disclosed |
| WO-2002042303-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-1056745-A2 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043676-A2 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |